Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dexcom (GB:0A4M)
LSE:0A4M
Dexcom (0A4M) Share Price & Analysis
1 Followers
0A4M Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$74.71 - $141.97
Previous Close$134.85
Volume12.85K
Average Volume (3M)3.36K
Market Cap
$51.66B
Enterprise Value$53.63B
Total Cash (Recent Filing)$566.30M
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)N/A
Beta0.90
Next Earnings
Jul 25, 2024EPS Estimate
$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding385,515,421
10 Day Avg. Volume326
30 Day Avg. Volume3,356
Standard Deviation0.12
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)27.87
Price to Sales (P/S)28.13
Price to Cash Flow (P/CF)99.60
P/FCF Ratio154.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.81
Enterprise Value/Gross Profit23.43
Enterprise Value/Ebitda58.20
Forecast
1Y Price Target
$154.13Price Target Upside11.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Dexcom News
PremiumStock Analysis & Ideas
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
Bulls Say, Bears Say
Bulls Say
Legal And Competitive PositionFavorable court ruling for Dexcom ensures strong legal footing, diminishing infringement concerns related to their sensor technology, and analysts maintain a buy rating, affirming confidence in the company's market position.
Product Approval And Market ExpansionFDA's approval of Dexcom's Stelo as the first over-the-counter CGM for type 2 non-insulin users expands market access, tapping into a broad patient pool and potentially accelerating revenue growth.
Strategic Market PenetrationDexcom's strategic initiatives, including direct-to-consumer marketing and increased sales efforts for Stelo, alongside ongoing trials for reimbursement, are poised to significantly bolster the product's market penetration and value proposition.
Bears Say
Legal IssuesDexcom faces potential setbacks due to a patent infringement verdict related to their inserter technology.
Product CompetitivenessRoche's Accu-Check SmartGuide CGM's higher MARD might limit its competitiveness in the precise continuous glucose monitoring market.
Product ReliabilityConcerns arise as approximately 20% of sensors may fail before their intended 15-day lifespan, potentially affecting user trust and product reliability.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.91% Insiders
36.23% Mutual Funds
25.81% Other Institutional Investors
35.06% Public Companies and
Individual Investors
0A4M FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest share price was $74.71 and its highest was $141.97 in the past 12 months.
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 25, 2024 which is in 88 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Apr 25, 2024. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.271 by $0.049.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is $0.39.
How many shares outstanding does Dexcom have?
Dexcom has 385,515,400 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.32 in its last earnings report, beating expectations of $0.271. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Dexcom?
Among the largest hedge funds holding Dexcom’s share is Sands Capital Management LLC. It holds Dexcom’s shares valued at 2B.
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.13 (11.87% Upside)
$154.13 (11.87% Upside)
Blogger Sentiment
Bullish
GB:0A4M Sentiment 86%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.33%
12-Months-Change
Fundamentals
Return on Equity
25.78%
Trailing 12-Months
Asset Growth
16.19%
Trailing 12-Months
Company Description
Dexcom
California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.
---
0A4M Company Deck
---
0A4M Earnings Call
Q1 2024
0:00 / 0:00
---
0A4M Revenue Breakdown
72.48% U.S.
27.52% Outside of the U.S.
---
0A4M Stock 12 Months Forecast
Average Price Target
$154.13
▲(11.87% Upside)
Technical Analysis
Best Analysts Covering 0A4M
1 Year
1 Year Success Rate
17/19 ratings generated profit
1 Year Average Return
+40.88%
reiterated a buy rating 7 months ago
Copying Mathew Blackman's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +40.88% per trade.
---